Orchard Therapeutics PLC
Jingjing Li currently serves as Associate Director of Global Quality Compliance at Orchard Therapeutics, where responsibilities include advancing a compliant Quality Management System and overseeing validation of computerized systems. Previous roles at Orchard include Associate Director of GMP Quality Assurance and Interim CMC Lead, focusing on quality oversight and collaboration with stakeholders on product submissions. Prior to Orchard, Jingjing held the position of Quality Assurance Lead at Cell and Gene Therapy Catapult, played a managerial role in Cell Therapy Operations at Lonza, and served as Senior QA/RA Engineer at Vela Diagnostics. Experience also encompasses operational quality management at Sanofi Pasteur and various research and consultancy roles. Jingjing holds a Master of Biotechnology from the University of Toronto and a Bachelor of Science in Bio-Medical Science from the University of Guelph.
This person is not in the org chart
This person is not in any teams
Orchard Therapeutics PLC
3 followers
Orchard Therapeutics plc, formerly Orchard Rx Ltd, is a commercial-stage, fully-integrated biopharmaceutical company. It is engaged in manufacturing and commercialization of gene and cell therapies, position to provide transformative therapies to patients suffering from a range of rare diseases. The Company is focused on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders and hemoglobinopathies. Its portfolio includes Strimvelis, its commercial-stage gammaretroviral-based product for the treatment of ADA-SCID five lentiviral product candidates in clinical-stage development and several other product candidates in preclinical development. It is developing OTL-101 as an autologous ex vivo lentiviral gene therapy to sustainably treat patients with adenosine deaminase severe combined immunodeficiency (ADA-SCID) through a single administration.